Antibodies News and Research

RSS

Biogen Idec's revenue increases 51% to $2.1 billion in first quarter 2014

Biogen Idec Inc. today reported first quarter 2014 results, including revenue of $2.1 billion, a 51% increase compared to the first quarter of 2013.

23 Apr 2014

Alexion Pharmaceuticals obtains orphan drug designation from EC for Soliris

Alexion Pharmaceuticals, Inc. today announced that the European Commission has granted an orphan drug designation (ODD) to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of graft rejection following solid organ transplantation. Graft rejection can cause severe injury to the transplanted organ and is a significant barrier to successful transplantation.

23 Apr 2014

New studies may offer hope for people with migraine

Two new studies may offer hope for people with migraine. The two studies released today will be presented at the American Academy of Neurology's 66th Annual Meeting in Philadelphia, April 26 to May 3, 2014.

23 Apr 2014

Findings may help researchers develop future interventions to prevent malaria

According to a study published today in PLOS Pathogens, children who live in regions of the world where malaria is common can mount an immune response to infection with malaria parasites that may enable them to avoid repeated bouts of high fever and illness and partially control the growth of malaria parasites in their bloodstream.

22 Apr 2014

XBiotech announces results from Phase I/II oncology study

XBiotech is announcing that results from its Phase I/II oncology study conducted at MD Anderson Cancer Center in Houston, TX were published today in Lancet Oncology. The featured article describes the outcome in 52 advanced cancer patients treated with Xilonix™, XBiotech's novel, non-cytotoxic, anti-tumor therapy.

18 Apr 2014

Study: HIV-positive women respond well to vaccine against human papillomavirus

HIV-positive women respond well to a vaccine against the human papillomavirus (HPV), even when their immune system is struggling, according to newly published results of an international clinical trial.

17 Apr 2014

Epirus Biopharmaceuticals to merge with Zalicus

Zalicus Inc., and Epirus Biopharmaceuticals, Inc., a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced today that they have entered into a definitive agreement under which Epirus will merge with a wholly-owned subsidiary of Zalicus in an all-stock transaction.

16 Apr 2014

Study: Bacterium that causes whooping cough changes in Australia

The bacterium that causes whooping cough, Bordetella pertussis, has changed in Australia - most likely in response to the vaccine used to prevent the disease - with a possible reduced effectiveness of the vaccine as a result, a new study shows.

16 Apr 2014

PolyTherics extends ThioBridge antibody drug conjugate collaboration with MacroGenics

PolyTherics Limited, a provider of technologies and services to enable the development of better biopharmaceuticals, today announced an extension to its ThioBridge antibody drug conjugate ("ADC") collaboration with MacroGenics Inc, a US biotechnology company developing innovative medicines utilizing its next generation antibody technologies.

11 Apr 2014

Guidance on use of Tamiflu needs to be reviewed in light of most recent evidence

Tamiflu (the antiviral drug oseltamivir) shortens symptoms of influenza by half a day, but there is no good evidence to support claims that it reduces admissions to hospital or complications of influenza.

11 Apr 2014

Experts and entrepreneurs to gather at 2014 Biotech China on 14-16 May

With just one month until 2014 Biotech China, experts, entrepreneurs and decision-makers from the international biotechnology industry will gather at the heart of the Chinese biotechnology industry on May 14-16th, 09:00 AM-06:00 PM in Nanjing China.

10 Apr 2014

Affimed Therapeutics reports additional results from AFM13 phase 1 study on R/R Hodgkin lymphoma

Affimed Therapeutics AG announced today further results from its phase 1 clinical trial of AFM13 as monotherapy for the treatment of patients with advanced relapsing/refractory (R/R) Hodgkin lymphoma.

10 Apr 2014

NIH study could offer clues for developing new antiviral treatments

A National Institutes of Health study reports that a rare genetic disease, while depleting patients of infection-fighting antibodies, may actually protect them from certain severe or recurrent viral infections.

10 Apr 2014

ImmunoGen presents first findings aimed at optimizing dosage of IMGN853 product candidate

ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the first findings from Company research aimed at optimizing the dosing of its IMGN853 product candidate.

9 Apr 2014

Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Janssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA™ (ibrutinib) to the U.S. Food and Drug Administration (FDA) by its collaboration partner Pharmacyclics, Inc.

8 Apr 2014

PeptiDream develops novel macrocyclic peptide inhibitor for treatment of multiple influenza strains

PeptiDream Inc., a public Tokyo-based biopharmaceutical company ("PeptiDream")( TOKYO:4587) announced today, in collaboration with The Tokyo Metropolitan Institute of Medical Science ("Tokyo Metropolitan Institute") the discovery and development of a novel macrocyclic peptide inhibitor for the treatment of multiple influenza strains.

8 Apr 2014

Dream team aims to turn pancreatic cancer into treatable disease

UC San Francisco has been selected to join a national "dream team" on pancreatic cancer, part of a project designed to accelerate treatment and discoveries for one of the most deadly forms of cancer.

8 Apr 2014

Magnetic nanoparticle (mNP) hyperthermia in breast cancer treatment

In a presentation exploring the promise of magnetic nanoparticle (mNP) hyperthermia in breast cancer treatment, Dartmouth researcher P. Jack Hoopes, DMV, PhD, reviewed preclinical studies conducted at Norris Cotton Cancer Center and discuss plans for early-phase clinical studies in humans at the annual meeting of the American Association for Cancer Research (AACR).

8 Apr 2014

Bio-Techne makes $10M equity investment in CyVek

Techne Corporation, d/b/a Bio-Techne, announced today that it has made a $10 million equity investment in CyVek, Inc. (CyVek), with a commitment to acquire CyVek if certain future milestones are met.

4 Apr 2014

FDA clears Omeros' OMS721 IND for inhibition of complement‑mediated TMAs

Omeros Corporation today announced that its Investigational New Drug Application (IND) to evaluate OMS721 for the inhibition of complement‑mediated thrombotic microangiopathies (TMAs) has been cleared by the U.S. Food and Drug Administration.

3 Apr 2014